Swedish Orphan Biovitrum AB today announces that Geoffrey McDonough will leave Sobi on 1 July 2017, and that a search for a new Chief Executive Officer has been initiated to identify his successor.
“Geoffrey McDonough has created remarkable value in his term as CEO. Under his leadership Sobi has become a prominent rare disease biotech company with a vibrant and growing commercial portfolio and significant growth potential ahead”, says Håkan Björklund, Chairman of the Board of Sobi, “Given the increasing demand and focus of our business in Europe, the Board has decided that Sobi needs more continuous presence in Stockholm than Geoffrey can sustain given his current location in Boston.”
“Sobi stands today on the platform of a strong and unique rare disease position supported by several years of strong financial results”, says Geoffrey McDonough, CEO and President of Sobi, “The Company is entering a period of unprecedented growth and opportunity that will benefit from local leadership.”
The company will host an investor and analyst conference call on 9 January at 12:30 pm CET, where Geoffrey McDonough, CEO and Håkan Björklund, Chairman of the Board, will make a brief statement and will be available for questions.
Source: Sobi
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.